In order to test our hypothesis that simultaneous inhibition of BCL-2 and Onc-p53 induces synergistic anticancer activity in a subset of SCLC-A and SCLC-P, we chose two BCL-2 high SCLC-P cell lines, H1048 and H211 to down-regulate Onc-p53 (R273C in H1048 and R248Q in H211) by shRNA (scrambled shRNA was used as a control). This evidence concerns the gene BCL2 and small cell lung carcinoma.